



August 27, 2024

AIN HOLDINGS INC.

Representative: Kiichi Otani, President and Representative Director

(Stock code 9627: Tokyo Prime Market, Sapporo Securities Exchange)

Inquiries: Toshihide Mizushima, Representative Senior Managing Director

TEL: +81-3-5333-1812

(Corrections) Partial Corrections to the Timely Disclosure Material

“Notice of Company Split (Absorption-Type Company Split) Between Consolidated Subsidiaries”

AIN HOLDINGS INC. hereby announces corrections to timely disclosure material, “Notice of Company Split (Absorption-Type Company Split) Between Consolidated Subsidiaries” released on August 21, 2024, as follows. Corrections are underlined.

Corrected parts

p.2 3. Overview of the companies involved

(Before correction)

	Splitting company
(8) Net assets	<u>¥7,477 million</u>
(9) Total assets	<u>¥22,551 million</u>
(10) Net assets per share	<u>¥154,180.21</u>
(17) Profit per share	<u>¥20,701,196.33</u>

(After correction)

	Splitting company
(8) Net assets	<u>¥8,423 million</u>
(9) Total assets	<u>¥23,765 million</u>
(10) Net assets per share	<u>¥175,526.71</u>
(17) Profit per share	<u>¥20,701.20</u>

p.3 5. Situation after the absorption-type company split

(Before correction)

After the absorption-type company split, the fiscal year-end for Francfranc will be April 30. There will be no other changes to the company name, business activities, head office location, title and name of representative, capital, or fiscal year of Francfranc. In addition, there will be no changes to the company name, business activities, head office location, title and name of representative, capital, or fiscal year of AIN PHARMACIEZ.



(After correction)

After the absorption-type company split, the fiscal year-end for Francfranc will be April 30. There will be no other changes to the company name, business activities, head office location, title and name of representative, or capital of Francfranc. In addition, there will be no changes to the company name, business activities, head office location, title and name of representative, capital, or fiscal year of AIN PHARMACIEZ.

Please refer to the following for the corrected timely disclosure material.

“Notice of Company Split (Absorption-Type Company Split) Between Consolidated Subsidiaries (Corrected Version)”

https://www.ainj.co.jp/corporate/assets/upload/news/20240821newsrelease_E.pdf